SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]

13295 reported adverse events

Drugs of this class: REMDESIVIR

These side effects are most commonly reported by patients taking drugs of the SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] class:

# Side effect Count
0 OFF LABEL USE 2245
1 ALANINE AMINOTRANSFERASE INCREASED 935
2 COVID-19 919
3 DRUG INEFFECTIVE 768
4 DEATH 762
5 BRADYCARDIA 652
6 ACUTE KIDNEY INJURY 630
7 ASPARTATE AMINOTRANSFERASE INCREASED 629
8 RESPIRATORY FAILURE 552
9 COVID-19 PNEUMONIA 505
See all common reactions for SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]

Drugs of the SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CLINICAL TRIAL PARTICIPANT 21 0.3684
1 COVID-19 TREATMENT 21 0.3088
2 RHINOCEREBRAL MUCORMYCOSIS 39 0.1124
3 CRYPTOCOCCAL MENINGOENCEPHALITIS 13 0.0992
4 CUTANEOUS MUCORMYCOSIS 15 0.0815
5 BRONCHOPLEURAL FISTULA 29 0.0771
6 PULMONARY MUCORMYCOSIS 36 0.0682
7 HUMORAL IMMUNE DEFECT 16 0.0431
8 COVID-19 PNEUMONIA 505 0.0427
9 HERPES SIMPLEX REACTIVATION 15 0.0394
See all enriched reactions for SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC]